Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
Other Sizes |
|
Targets |
IL-6
|
---|---|
ln Vitro |
Tocilizumab, also known as humanized antibody or anti-human IL6R, reduces cell proliferation (growth rate) in a dose-dependent manner. At 100 ng/mL, HACM exhibits an almost total reduction in growth rate [2]. The humanized antibody tocilizumab (0.001-10,000 μg/mL; 2 days) has an IC50 of 13.5 ng/mL and suppresses the proliferation of Ba/F3-gp130-IL-6R cells stimulated with hIL-6[1]. In accordance with SAS cells in vivo, tocilizumab (humanized antibody, anti-human IL6R) (1 μM; 6 hours) decreases STAT3 phosphorylation in vitro [3]. In serum-free media, tocilizumab (humanized antibody against human IL6R) (1–5 μM; 24 hours) dramatically lowers the production of VEGF mRNA in SAS cells [3].
|
ln Vivo |
In the brains of mice injected with tocilizumab, the volume of each metastasis was decreased (iv; 1.0 mg/100 μL; twice weekly for three weeks)[2]. Tocilizumab is an anti-human IL6R, humanized antibody. Tocilizumab, an intraperitoneal injection administered at 100 μg/mL every 48 hours for 20 days, is a humanized antibody that blocks the progression of OSCC and prevents tumor angiogenesis[3]. br>
|
Cell Assay |
Cell Proliferation Assay[2]
Cell Types: Human-derived HARA-B cells Tested Concentrations: 1 ng/mL, 10 ng/mL, and 100 ng/mL Incubation Duration: 24 hrs (hours), 48 hrs (hours) Experimental Results: Inhibited the IL-6R expressed on human-derived HARA-B cells. Cell Cytotoxicity Assay[1] Cell Types: Ba/F3-gp130-IL-6R cells Tested Concentrations: 0.001–10000 μg/ml Incubation Duration: 2 days Experimental Results: Inhibited Ba/F3-gp130-IL -6R cell proliferation. Western Blot Analysis[3] Cell Types: SAS cells Tested Concentrations: 1 μM Incubation Duration: 6 hrs (hours) Experimental Results: diminished the phosphorylation of STAT3. RT-PCR[3] Cell Types: SAS cells Tested Concentrations: 1-5 μM Incubation Duration: 24 hrs (hours) Experimental Results: diminished VEGF mRNA expression. |
Animal Protocol |
Animal/Disease Models: A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice[2]
Doses: 1.0 mg/100 μL Route of Administration: intravenous (iv) injection; 1.0 mg/100 μL; twice a week, three weeks Experimental Results: Led the volume of each metastatic focus Dramatically smaller. Animal/Disease Models: SCID (severe combined immunodeficient) mouse with SAS cells[3] Doses: 100 μg/mL Route of Administration: intraperitoneal (ip) injection;100 μg/mL; every 48 hrs (hours); 20days Experimental Results: Suppressed the growth of advanced tumors. |
References |
[1]. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70.
[2]. Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526. [3]. Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34. [4]. Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954. |
CAS # |
375823-41-9
|
---|---|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.